

1 **Detection of dynamic lung hyperinflation using cardiopulmonary exercise testing and**
2 **respiratory function in patients with stable cardiac disease: a multicenter cross-sectional study**

3

4 Kazuyuki Kominami¹, Kazuki Noda², Nanaho Minagawa³, Kazuya Yonezawa⁴, Masanori Ueda⁵,
5 Yasuyuki Kobayashi⁶, Makoto Murata⁷, and Masatoshi Akino⁸

6

7 1 Kazuyuki Kominami, M.S.

8 Department of Rehabilitation, Sanseikai Kitano Hospital, Sapporo, Hokkaido, Japan

9 e-mail; qqac3s4u9@gmail.com

10

11 2 Kazuki Noda

12 Department of Rehabilitation, National Hospital Organization Hakodate Hospital, Hakodate, Japan

13 e-mail; knoda@hnh.hosp.go.jp

14

15 3 Nanaho Minagawa

16 Sinfuwakai Asabu Heart and Cardiac Rehabilitation Clinic, Sapporo, Hokkaido, Japan

17 e-mail; minanaho@gmail.com

18

19 4 Kazuya Yonezawa, M.D. Ph.D.

20 Department of Cardiovascular Medicine, National Hospital Organization Hakodate Hospital,

21 Hakodate, Hokkaido, Japan

22 e-mail; kyonezaw@hnh.hosp.go.jp

23

24 5 Masanori Ueda

25 Department of Clinical Laboratory, Gunma Prefectural Cardiovascular Center, Maebashi, Gunma,

26 Japan

27 e-mail; ueda-masa@outlook.jp

28

29 6 Yasuyuki Kobayashi

30 Department of Clinical Laboratory, Gunma Prefectural Cardiovascular Center, Maebashi, Gunma,

31 Japan

32 e-mail; koba@cvc.pref.gunma.jp

33

34 7 Makoto Murata, M.D. Ph.D.

35 Gunma Prefectural Cardiovascular Center, Department of Cardiology, Maebashi, Gunma, Japan

36 e-mail; yarukimanmann2000@yahoo.co.jp

37

38 8 Masatoshi Akino, M.D. Ph.D.

39 Department of Orthopedics, Sapporo Kiyota Orthopedic Hospital, Sapporo, Hokkaido, Japan

40 e-mail; akimasa07@gmail.com

41

42 **Corresponding Author Name:**

43 Kazuyuki Kominami

44 6-30, 1-chome, Kitano 1-jyo, Kiyota-ku, Sapporo, Japan 004-0861

45 Phone: +81-11-883-0121

46 Fax: +81-11-883-7261

47 E-mail address: qqae3s4u9@gmail.com

48

49 **Short title:** dynamic lung hyperinflation and exercise testing

50

51 **Conflicts of Interest and Source of Funding:**

52 This study received no funding. The authors declare no conflict of interest. The results of this study

53 do not constitute an endorsement by the *Journal of American Heart Association*.

54

55 **Total word count of the manuscript (including the title page, abstract, text, references, table,**

56 **table and figure legends):** 5643 words

57

58 **Keywords:** dynamic lung hyperinflation, air trapping, tidal volume, cardiopulmonary exercise

59 testing, respiratory function

60

61 Abstract

62 Background: Many patients with heart disease potentially have comorbid COPD, however there are
63 not enough opportunities for screening and the qualitative differentiation of shortness of breath
64 (SOB) has not been well established. We investigated the detection rate of SOB based on a visual
65 and qualitative dynamic lung hyperinflation (DLH) detection index during cardiopulmonary exercise
66 testing (CPET) and whether there was a difference in respiratory function between the two groups.

67

68 Methods: We recruited 534 patients with heart disease and to scrutinize physical functions (369
69 males, 67.0 ± 12.9 years) who underwent CPET and spirometry simultaneously. The difference
70 between inspiratory and expiratory tidal volume was calculated (TV E-I) from the breath-by-breath
71 data. A TV E-I decrease after the start of exercise comprised the convex group, and a TV E-I that
72 remained unchanged or increased comprised the non-convex group.

73

74 Results: 129 patients (24.2%) were in the convex; there was no difference in clinical characteristics
75 between groups. The Borg scale scores at the end of the CPET showed no difference. VE/VCO₂
76 slope, its Y-intercept and minimum VE/VCO₂ showed no significant difference. In the convex group,
77 FEV_{1.0%} was significantly lower (69.4 ± 13.1 vs. $75.0 \pm 9.0\%$), and FEV_{1.0%} and Y-intercept and the
78 difference between minimum VE/VCO₂ and VE/VCO₂ slope were significantly correlated ($r =$

79 -0.343 and $r=-0.478$).

80

81 Conclusions: The convex group showed decreased respiratory function, suggesting potential airway

82 obstruction during exercise. A combined assessment of the TV E-I and Y-intercept of the VE/VCO₂

83 slope or the difference between the minimum VE/VCO₂ and VE/VCO₂ slopes could potentially

84 detect COPD or airway obstruction.

85

86 Word count: 249 words

87

88

89 Introduction

90 Patients with cardiovascular diseases usually suffer from respiratory diseases such as
 91 chronic obstructive pulmonary disease (COPD) [1-3], and develop fatigue and shortness of breath
 92 because of a variety of factors that limit exercise and activity, including lifestyle factors such as
 93 inactivity [4], increased left ventricular filling pressures [5], ventilatory-perfusion mismatch [6], and
 94 impaired oxygen delivery capacity because of cardiac dysfunction [7]. Current smoking or
 95 ex-smoking are common coronary risk factors and exacerbating factors of chronic heart failure
 96 [8-12]. In addition, poor lung function is an independent risk factor for cardiovascular disease and
 97 atrial fibrillation (AF) [13-17], and subclinical respiratory impairment is associated with the
 98 development of hypertension, which is a major risk factor for cardiovascular disease and mortality
 99 [18]. However, comorbid COPD without a history of smoking [19], potentially comorbid COPD, or
 100 respiratory impairment may not be adequately assessed, and this has not led to early detection of
 101 COPD or respiratory impairment in patients with heart disease [20].

102 Airflow obstruction in COPD is caused by decreased pulmonary elastic contractile
 103 pressure because of peripheral airway involvement and emphysematous lesions, resulting in
 104 collapsed airways and air trapped in the lungs during forced expiration (referred to as “air trapping”).
 105 Collapsed peripheral airways also occur during resting breathing as the disease progresses,
 106 contributing to lung hyperinflation [21]. In addition, air trapping, caused by collapsed peripheral

107 airways, is strengthened with exertion or exercise, causing further lung hyperinflation. This is called
108 dynamic lung hyperinflation (DLH) and is an important factor in patients with COPD, contributing
109 to increased respiratory workload, shortness of breath on exertion, and reduced exercise tolerance
110 [22, 23]. Although measurement of inspiratory capacity (IC) during exercise testing or the
111 hyperventilation method has been proposed to assess DLH [24-29], opportunities for screening are
112 insufficient. In contrast, there have been several reports combining exercise testing and inspiratory
113 reserve capacity; however, there are limited reports on cardiopulmonary exercise testing (CPET),
114 which is the most standard method of assessing exercise tolerance [30-35]. Furthermore, CPET, the
115 gold standard for assessing exercise tolerance, provides information on the index of exercise
116 tolerance. In CPET, the Y-intercept of the linear carbon dioxide production (CO_2) and minute
117 ventilation (VE) relationship (the VE/VCO_2 slope) is related to the severity of COPD and the forced
118 expiratory volume (FEV) in 1 s (FEV_{1.0}) as a percentage of forced vital capacity (FEV 1.0%) [36].
119 In previous studies, we have attempted to use CPET measurements to visually and qualitatively
120 detect the DLH [37]. In this method, the difference between the expiratory and inspiratory tidal
121 volumes is measured during incremental exercise, and expiration is assumed to be reduced relative
122 to inspiration when dynamic lung hyperinflation occurs.

123 In this study, we hypothesized that the presence or absence of the DLH index would be
124 correlated with the CPET indices and respiratory function. By clarifying the relationship between the

125 presence or absence of the indicators of DLH, CPET, and respiratory function, we believe a detailed
126 evaluation of respiratory function using CPET is possible. In addition, identifying respiratory
127 impairment by CPET in asymptomatic or very mild stages of COPD will permit early preventive
128 intervention and help prevent disease exacerbation.

129

130

131 **Methods**

132

133 We included 534 patients with stable heart disease and to scrutinize physical functions
134 (age: 67.0 ± 12.9 years [95%CI: 65.9–68.1], height: 161.9 ± 9.2 cm [95%CI: 161.2–162.7], body
135 weight: 62.5 ± 14.6 kg [95%CI: 61.3–63.7], BMI: 23.7 ± 4.4 kg/m² [95%CI: 23.3–24.1]) who
136 underwent CPET and spirometry testing approximately the same time.

137

138 The CPET was performed using a stationary bicycle (StrengthErgo 8; Mitsubishi Electric
139 Engineering, Tokyo, COMBI 75XL3; Konami Sports Co., Ltd., Tokyo) on a breath-by-breath basis
140 with a gas analyzer (AE-300S or AE-310S; Minato Ikagaku Co., Tokyo). The maximal symptomatic
141 exercise was performed using the ramp protocol. The exercise protocol consisted of 2–3 minutes of
142 rest and 2–3 minutes of warm-up (W.U). The ramp protocol was adjusted to 10–20 W/min, assuming
143 the individual exercise tolerance level. The rating of perceived exertion (RPE) at the end of the
144 exercise was assessed using the Borg scale.

145 Furthermore, a breath-by-breath gas analyzer (AE-300S or AE-310S; Minato Ikagaku Co.,
146 Tokyo) was used to measure the ventilatory volume of each breath using a hot-wire flowmeter [38].
147 Before each exercise testing, we calibrated the test appropriately according to standard protocols.

148

149 **Calculation of cardiopulmonary exercise testing measurements**

150 We calculated the difference between inspiratory and expiratory tidal volumes (TV I and E,
151 respectively) for each breathing from breath-by-breath data in each CPET [37]. Further, we have
152 defined the difference between the expiratory and inspiratory tidal volumes to “TV E-I.” We plotted
153 TV E-I against the time axis. In addition, we calculated the mean and standard deviation of TV E-I
154 per minute based on the start of the W.U (zero).

155 We extracted other CPET parameters, such as the VE/CO₂ slope and the Y-intercept,
156 minimum VE/VCO₂, VO₂/HR, and dead-space gas volume to tidal volume ratio (VD/VT) for each
157 case.

158

159 **Spirometry testing**

160 Spirometry testing was performed following standard methods using respiratory function
161 testing equipment (mainly electronic diagnostic spirometer Spiroshift SP-770 COPD Fukuda Denshi
162 Co., Tokyo).

163

164 **Statistical analysis**

165 Data were presented as mean ± standard deviation (SD) and 95% confidence intervals. In
166 addition, unpaired data were analyzed using the Student's t-test. In contrast, paired data were

167 analyzed using a paired t-test. Furthermore, plots of FEV1.0% and Y-intercept of VE/VCO₂ slope,
168 the difference between minimum VE/VCO₂ and VE/VCO₂ slope were linearly regressed, and
169 regression equations and coefficients were calculated. Statistical analyses were performed using
170 Statistics for Excel 2012 (Social Survey Research Information Co., Tokyo, Japan).

171

172 **Ethical considerations**

173 The study was conducted following the principles outlined in the Declaration of Helsinki
174 and approved by the ethical committees of Hakodate National Hospital (approval number:
175 R4-0314001) and Gunma Prefectural Cardiovascular Center (approval number:2022020).

176 The data obtained were delinked and anonymized, and this study was conducted using the
177 data for analysis, with due consideration for protecting the participants' personal information. The
178 authors confirmed that none of the participants could be identified, and they were fully anonymized.
179 Furthermore, the authors affirmed that all mandatory health and safety procedures complied with the
180 course of conducting the experimental work reported in this paper.

181

182

183 **Results**

184

185 There were no differences in physical parameters between the convex and non-convex
186 groups; however, there were significantly more males in the convex group. Although there was no
187 significant difference in smoking history between the two groups (Smoking history (+/-) Total
188 339:195, convex 85:44, non-convex 254:151, $p = 0.514$), the convex group had more severe cases
189 when the GOLD classification was applied (GOLD classification (0:I:II:III:IV); total 397:86:39:9:3,
190 convex 79:24:15:8:3, non-convex 318:62:24:1:0, $p < 0.001$) (Table1).

191 Furthermore, all the participants underwent CPET for symptomatic maximal. Moreover,
192 there were 129 patients in the convex group with decreased TV E-I during CPET and 405 patients in
193 the non-convex group. Although the rating of perceived exertion at the end of the exercise test
194 showed no difference in shortness of breath between the two groups, lower extremity fatigue was
195 significantly lower in the convex group.

196

197 **The indices of cardiopulmonary exercise testing**

198 A list of typical CPET parameters is shown in Table 2. There were no significant
199 differences in the exercise tolerance indices between the two groups. Although there were no
200 differences in the VE/VCO₂ slope and Y-intercept between the two groups, the minimum VE/VCO₂

201 tended to be higher in the convex group.

202

203 **The indices of spirometry testing**

204 Ventilatory capacity (VC), tidal volume (TV), expiratory reverse volume (ERV) and

205 inspiratory reverse volume (IRV) did not differ significantly. However, the convex group had

206 significantly lower FEV1.0% and predictive rates for %FEV1.0, %PEF, and %MVV.

207

208 **Relationship between exhaled gas analysis index and spirometry testing**

209 In the convex group, Y-intercept and FEV1.0% showed a significant negative correlation

210 (convex; $r=-0.343$ [$-0.487 \leq \rho \leq -0.181$], $p<0.001$, non-convex; $r=-0.090$ [$-0.186 \leq \rho \leq 0.008$],

211 $p=0.070$) (Figure 1 (A-1, 2)).

212 VE/VCO₂ slope and minimum VE/CCO₂ showed little correlation with FEV1.0%;

213 however, there was a significant negative correlation with the difference between VE/VCO₂ slope

214 and minimum VE/VCO₂ (convex; $r=-0.478$ [$-0.601 \leq \rho \leq -0.333$], $p<0.001$, non-convex; $r=-0.137$

215 [$-0.231 \leq \rho \leq -0.040$], $p=0.006$) (Figure 1 (B-1, 2)).

216

217

218 Discussion

219 This is the first study to examine the relationship between differences in respiratory
220 function and CPET indices based on the qualitative detection of DLH using CPET. DLH is a
221 physiological respiratory mechanism in which expiration occurs less than inspiration, with an
222 increased respiratory rate. Based on this theory, we showed in this study that DLH could be easily
223 detected and correlated with respiratory function by analyzing data from exhaled gas analyses.

224

225 Respiratory function by spirometry testing

226 Respiratory functions, such as VC and TV, did not differ between the two groups; however,
227 FEV1.0%, %MVV, and %PEF were lower in the convex group. In the convex group, the mean value
228 of FEV1.0% was equivalent to the diagnostic criteria for obstructive ventilatory impairment. In
229 contrast, in the non-convex group, most cases did not meet the criteria for GOLD stage 1, and
230 several cases were not diagnosed as having obstructive ventilation impairment on spirometry testing.
231 Nevertheless, several patients in the convex group likely had DLH because of peripheral airway
232 obstruction (stenosis) or other factors, as they had less expiration than inspiration during the exercise.
233 Therefore, it is possible that respiratory function had already declined before the criteria for
234 diagnosis of DLH because of the obstruction of the small bronchioles and other organs. Furthermore,
235 it has already been shown that subclinical respiratory impairment may also affect cardiovascular

function and cardiovascular disease. Although this was a cross-sectional study and the outcome of very mild cases is unknown, we believe that TV E-I may be a qualitative indicator of peripheral airway obstruction.

Relationship between cardiopulmonary exercise testing indices and dynamic pulmonary hyperinflation

Ventilatory efficiency decreases because of congestion caused by heart failure and obstructive ventilation impairment [39]. For instance, in patients with heart failure, the minimum VE/VCO_2 and VE/VCO_2 slope increase with disease severity; however, they are generally consistent [40]. In contrast, in COPD, the VE/VCO_2 slope increases in mild disease but decreases in severe disease [41, 42]. Furthermore, it has been reported that in COPD, the Y-intercept of the VE/VCO_2 slope is related to FEV1.0%, and the Y-intercept is higher [36]. Murata et al. reported that as COPD progresses, the minimum VE/VCO_2 and VE/VCO_2 slopes may diverge, or the VE/VCO_2 slope may become pseudo-negative, and the Y-intercept may be high [36, 43]. However, both indices only report observational studies on COPD and do not examine the presence or absence of DLH or its extent.

Although the convex group showed a trend toward a higher minimum VE/VCO_2 in this study, there were no significant differences in these indices between the two groups, including the

254 Y-intercept and VE/VCO₂ slope. However, even in such cases, FEV1.0% and the Y-intercept of the
255 VE/VCO₂ slope showed a significant correlation in the convex group, similar to the results of
256 previous studies. Furthermore, FEV1.0% also showed a significant negative correlation with the
257 difference between the minimum VE/VCO₂ ratio and the VE/VCO₂ slope. In contrast, in the
258 non-convex group, the correlation between the difference in minimum VE/VCO₂ and VE/VCO₂
259 slope and FEV1.0% was very limited, indicating that a combined evaluation with TV E-I is crucial.

260 Although the study group had milder respiratory function impairment than those in
261 previous studies, it was suggested that the combined TV E-I and Y-intercept or the difference
262 between the minimum VE/VCO₂ and VE/VCO₂ slope during incremental exercise testing could
263 provide an index of respiratory function and an assessment of the severity of peripheral airway
264 obstruction in patients with stable cardiac disease.

265

266 **The usefulness of detecting dynamic lung hyperinflation using cardiopulmonary exercise test**

267 Most participants in this study had stable heart disease and mild respiratory function
268 impairment. However, 63.4% of the patients had a smoking history, and more than 20% showed the
269 possibility of DLH on CPET. Interestingly, the prevalence of COPD is expected to decrease in
270 high-income countries as smoking declines; however, it will become a major social problem in
271 low-to-middle-income countries [44]. Thus, COPD causes chronic systemic inflammation, leading to

272 a decline in physical function and a worsening prognosis [45]. Moreover, DLH increases the
273 respiratory workload and restricts venous return [46], leading to exercise limitation and static lung
274 hyperinflation caused by COPD progression and a worsened prognosis [45,47,48].

275 We believe that capturing respiratory changes associated with increased exercise intensity
276 using CPET, as in this study, is a simple and qualitative method for detecting airway stenosis and
277 DLH at an early stage, even in patients with mild or asymptomatic symptoms. Furthermore, we
278 believe this will lead to early scrutiny, appropriate therapeutic interventions, and drug prescriptions,
279 thus, improving the quality of life and patient prognosis.

280

281

282 **Limitations**

283 There are several limitations to this study.

284 First, this was a cross-sectional study, and cardiopulmonary exercise and spirometry testing were not

285 often performed at approximately the same time, possibly resulting in a selection bias (comorbidity

286 of DLH). In addition, it is unclear about the course of the subjects in this study, whether there was

287 worsening shortness of breath and other factors, progressive decline in respiratory function, or a

288 diagnosis of COPD. Therefore, further studies are warranted.

289 Second, the study did not compare the results with those of the existing DLH assessment methods or

290 evaluate the response to bronchodilator use. Therefore, it is difficult to confirm the presence of DLH

291 based on the results of this study alone.

292 Third, several participants in this study had relatively preserved respiratory function. Therefore, it is

293 uncertain whether a similar trend would be observed in patients with moderate-to-severe COPD who

294 have already been diagnosed.

295 Finally, it is currently difficult to determine the severity of DLH; therefore, developing appropriate

296 analytical methods for TV E-I is desirable.

297

298 **Conclusion**

299 Evaluating data on differences in expiratory and inspiratory tidal volumes (TV E-I) during

300 cardiopulmonary exercise testing has proven useful for dynamic lung hyperinflation in patients with
301 stable heart disease. The combined evaluation of the TV E-I and Y-intercept of the VE/VCO_2 slope,
302 or the difference between the minimum VE/VCO_2 and VE/VCO_2 slopes in CPET, could detect cases
303 of potential respiratory impairment or peripheral airway obstruction.
304

305 **Abbreviations**

306 VAT: ventilatory anaerobic threshold; Inc-Ex: incremental exercise; CPET: Cardiopulmonary
 307 exercise testing; VO₂: Oxygen uptake; VCO₂: carbon dioxide production; VE: ventilatory
 308 equivalent; RPE: Rating of perceived exertion; RR: respiratory rate; VD/VT: dead-space gas volume
 309 to tidal volume ratio; COPD: chronic obstructive pulmonary disease; DLH: dynamic lung
 310 hyperinflation; TV: tidal volume; TV I: inspiratory tidal volume; TV E: expiratory tidal volume;
 311 FEV: forced expiratory volume; FEV_{1.0}: forced expiratory volume in 1 second; FEV 1.0%: forced
 312 expiratory volume in 1 second as a percent of forced vital capacity; VC: vital capacity; IC:
 313 inspiratory capacity;

314

315 **Acknowledgements**

316 We would like to thank Editage for assistance with English language editing.

317 The results of the study are presented clearly, honestly, and without fabrication,
 318 falsification, or inappropriate data manipulation, and the results of the present study do not constitute
 319 an endorsement by the *Journal of American Heart Association*.

320

321 **Authors' contributions**

322 KK, MM, and MA developed the study concept and were involved in its design and implementation.

323 KK, KN, NM, and MM delivered program content to the participants. KK, KN, NM, MU, YK, and
324 MM acquired data. KK analyzed the data. KK and MM prepared the manuscript. KN, MN, KY, and
325 MA drafted the manuscript and approved the final draft. All the authors have read and approved the
326 final version of the manuscript.

327

328 **Sources of Funding**

329 This study did not receive any funding support.

330

331 **Availability of data and materials**

332 The dataset used in this study is available from the corresponding author upon request.

333

334 **Ethics approval and consent to participate**

335 The study was conducted following the principles outlined in the Declaration of
336 Helsinki and was approved by the ethics committees of Hakodate National Hospital (approval
337 number: R4-1114006) and the Gunma Prefectural Cardiovascular Center (approval
338 number:2022020).

339 The data obtained were delinked and anonymized, and this study was conducted using the
340 data for analysis and due consideration to the protection of the participants' personal information.

341 Consequently, the authors confirmed that none of the participants could be identified, and they were
342 fully anonymized. Furthermore, the authors affirm that all mandatory health and safety procedures
343 complied with the course of conducting the experimental work reported in this paper.

344

345 **Consent for publication**

346 Not applicable.

347

348 **Competing interests**

349 The authors declare that they have no competing interests.

350

351

352 **References**

- 353 1. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and
354 chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. *Eur J Heart Fail.*
355 2009;11:130-139.
- 356 2. Correale M, Paolillo S, Mercurio V, Ruocco G, Tocchetti CG, Palazzuoli A. Non-cardiovascular
357 comorbidities in heart failure patients and their impact on prognosis. *Kardiol Pol.*
358 2021;79:493-502.
- 359 3. Anker SD, Butler J, Filippatos G, Shahzeb Khan M, Ferreira JP, Bocchi E, Böhm M,
360 Brunner-La Rocca HP, Choi DJ, Chopra V, et al.; EMPEROR-Preserved Trial Committees and
361 Investigators. Baseline characteristics of patients with heart failure with preserved ejection
362 fraction in the EMPEROR-Preserved trial. *Eur J Heart Fail.* 2020;22:2383-2392.
- 363 4. Okita K, Kinugawa S, Tsutsui H. Exercise intolerance in chronic heart failure--skeletal muscle
364 dysfunction and potential therapies. *Circ J.* 2013;77:293-300.
- 365 5. Sekiguchi M, Adachi H, Oshima S, Taniguchi K, Hasegawa A, Kurabayashi M. Effect of
366 changes in left ventricular diastolic function during exercise on exercise tolerance assessed by
367 exercise-stress tissue Doppler echocardiography. *Int Heart J.* 2009;50:763-771.
- 368 6. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, Franklin B, Guazzi
369 M, Gulati M, et al.; American Heart Association Exercise, Cardiac Rehabilitation, and

- 370 Prevention Committee of the Council on Clinical Cardiology; Council on Epidemiology and
371 Prevention; Council on Peripheral Vascular Disease; Interdisciplinary Council on Quality of
372 Care and Outcomes Research. Clinician's Guide to cardiopulmonary exercise testing in adults:
373 a scientific statement from the American Heart Association. *Circulation*. 2010;122:191-225.
- 374 7. Pandey A, Shah SJ, Butler J, Kellogg DL Jr, Lewis GD, Forman DE, Mentz RJ, Borlaug BA,
375 Simon MA, Chirinos JA, et al. Exercise Intolerance in Older Adults With Heart Failure With
376 Preserved Ejection Fraction: JACC State-of-the-Art Review. *J Am Coll Cardiol*.
377 2021;78:1166-1187.
- 378 8. Siasos G, Tsigkou V, Kokkou E, Oikonomou E, Vavuranakis M, Vlachopoulos C, Verveniots A,
379 Limperi M, Genimata V, Papavassiliou AG, et al. Smoking and atherosclerosis: mechanisms of
380 disease and new therapeutic approaches. *Curr Med Chem*. 2014;21:3936-3948.
- 381 9. Kamimura D, Cain LR, Mentz RJ, White WB, Blaha MJ, DeFilippis AP, Fox ER, Rodriguez CJ,
382 Keith RJ, Benjamin EJ, et al. Cigarette Smoking and Incident Heart Failure: Insights From the
383 Jackson Heart Study. *Circulation*. 2018;137:2572-2582.
- 384 10. Suskin N, Sheth T, Negassa A, Yusuf S. Relationship of current and past smoking to mortality
385 and morbidity in patients with left ventricular dysfunction. *J Am Coll Cardiol*.
386 2001;37:1677-1682.
- 387 11. van Oort S, Beulens JWJ, van Ballegooijen AJ, Handoko ML, Larsson SC. Modifiable lifestyle

- 388 factors and heart failure: A Mendelian randomization study. *Am Heart J.* 2020;227:64-73.
- 389 12. Lu Y, Xu Z, Georgakis MK, Wang Z, Lin H, Zheng L. Smoking and heart failure: a Mendelian
390 randomization and mediation analysis. *ESC Heart Fail.* 2021;8:1954-1965.
- 391 13. Johnson LS, Juhlin T, Engström G, Nilsson PM. Reduced forced expiratory volume is
392 associated with increased incidence of atrial fibrillation: the Malmo Preventive Project.
393 *Europace.* 2014;16:182-188.
- 394 14. Chahal H, Heckbert SR, Barr RG, Bluemke DA, Jain A, Habibi M, Alonso A, Kronmal R,
395 Jacobs DR Jr, Lima JA, et al. Ability of Reduced Lung Function to Predict Development of
396 Atrial Fibrillation in Persons Aged 45 to 84 Years (from the Multi-Ethnic Study of
397 Atherosclerosis-Lung Study). *Am J Cardiol.* 2015;115:1700-1704.
- 398 15. Li J, Agarwal SK, Alonso A, Blecker S, Chamberlain AM, London SJ, Loehr LR, McNeill AM,
399 Poole C, Soliman EZ, et al. Airflow obstruction, lung function, and incidence of atrial
400 fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. *Circulation.*
401 2014;129:971-980.
- 402 16. Engström G, Lind P, Hedblad B, Wollmer P, Stavenow L, Janzon L, Lindgärde F. Lung function
403 and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. *Circulation.*
404 2002;106:2555-2560.
- 405 17. Wang B, Zhou Y, Xiao L, Guo Y, Ma J, Zhou M, Shi T, Tan A, Yuan J, Chen W. Association of

406 lung function with cardiovascular risk: a cohort study. *Respir Res.* 2018;19:214.

407 18. Jacobs DR Jr, Yatsuya H, Hearst MO, Thyagarajan B, Kalhan R, Rosenberg S, Smith LJ, Barr

408 RG, Duprez DA. Rate of decline of forced vital capacity predicts future arterial hypertension:

409 the Coronary Artery Risk Development in Young Adults Study. *Hypertension.*

410 2012;59:219-225.

411 19. Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk

412 factors, pathogenesis, and implications for prevention and treatment. *Lancet Respir Med.*

413 2022;10:497-511.

414 20. Ramalho SHR, Shah AM. Lung function and cardiovascular disease: A link. *Trends Cardiovasc*

415 *Med.* 2021;31:93-98.

416 21. Kurosawa H, Kohzuki M. Images in clinical medicine. Dynamic airway narrowing. *N Engl J*

417 *Med.* 2004;350:1036.

418 22. O'Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during

419 high-intensity, constant-work-rate exercise in COPD. *J Appl Physiol (1985).*

420 2006;101:1025-1035.

421 23. Stringer W, Marciniuk D. The Role of Cardiopulmonary Exercise Testing (CPET) in Pulmonary

422 Rehabilitation (PR) of Chronic Obstructive Pulmonary Disease (COPD) Patients. *COPD.*

423 2018;15:621-631.

- 424 24. Fujimoto K, Kitaguchi Y, Kanda S, Urushihata K, Hanaoka M, Kubo K. Comparison of
425 efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant
426 chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2011;6:219-227.
- 427 25. Fujimoto K, Yamazaki H, Ura M, Kitaguchi Y. Efficacy of tiotropium and indacaterol
428 monotherapy and their combination on dynamic lung hyperinflation in COPD: a random
429 open-label crossover study. *Int J Chron Obstruct Pulmon Dis*. 2017;12:3195-3201.
- 430 26. Fujimoto K, Yoshiike F, Yasuo M, Kitaguchi Y, Urushihata K, Kubo K, Honda T. Effects of
431 bronchodilators on dynamic hyperinflation following hyperventilation in patients with COPD.
432 *Respirology*. 2007;12:93-99.
- 433 27. Kawachi S, Fujimoto K. Metronome-Paced Incremental Hyperventilation May Predict Exercise
434 Tolerance and Dyspnea as a Surrogate for Dynamic Lung Hyperinflation During Exercise. *Int J*
435 *Chron Obstruct Pulmon Dis*. 2020;15:1061-1069.
- 436 28. Kawachi S, Fujimoto K. Efficacy of tiotropium and olodaterol combination therapy on dynamic
437 lung hyperinflation evaluated by hyperventilation in COPD: an open-label, comparative before
438 and after treatment study. *Int J Chron Obstruct Pulmon Dis*. 2019;14:1167-1176.
- 439 29. Roesthuis LH, van der Hoeven JG, Guérin C, Doorduyn J, Heunks LMA. Three bedside
440 techniques to quantify dynamic pulmonary hyperinflation in mechanically ventilated patients
441 with chronic obstructive pulmonary disease. *Ann Intensive Care*. 2021;11:167.

- 442 30. Satake M, Shioya T, Uemura S, Takahashi H, Sugawara K, Kasai C, Kiyokawa N, Watanabe T,
443 Sato S, Kawagoshi A. Dynamic hyperinflation and dyspnea during the 6-minute walk test in
444 stable chronic obstructive pulmonary disease patients. *Int J Chron Obstruct Pulmon Dis*.
445 2015;10:153-158.
- 446 31. Alfonso M, Bustamante V, Cebollero P, Antón M, Herrero S, Gáldiz JB. Assessment of dyspnea
447 and dynamic hyperinflation in male patients with chronic obstructive pulmonary disease during
448 a six minute walk test and an incremental treadmill cardiorespiratory exercise test. *Rev Port*
449 *Pneumol (2006)*. 2017;23:266-272.
- 450 32. Chen R, Lin L, Tian JW, Zeng B, Zhang L, Chen X, Yan HY. Predictors of dynamic
451 hyperinflation during the 6-minute walk test in stable chronic obstructive pulmonary disease
452 patients. *J Thorac Dis*. 2015;7:1142-1150.
- 453 33. Cordoni PK, Berton DC, Squassoni SD, Scuarcialupi ME, Neder JA, Fiss E. Dynamic
454 hyperinflation during treadmill exercise testing in patients with moderate to severe COPD. *J*
455 *Bras Pneumol*. 2012;38:13-23.
- 456 34. Shiraishi M, Higashimoto Y, Sugiya R, Mizusawa H, Takeda Y, Fujita S, Nishiyama O, Kudo S,
457 Kimura T, Chiba Y, et al. Diaphragmatic excursion correlates with exercise capacity and
458 dynamic hyperinflation in COPD patients. *ERJ Open Res*. 2020;6:00589-2020.
- 459 35. Vieira DSR, Mendes LPS, Alencar MCN, Hoffman M, Albuquerque ALP, Silveira BMF, Aguiar

- 460 SC, Parreira VF. Rib cage distortion and dynamic hyperinflation during two exercise intensities
461 in people with COPD. *Respir Physiol Neurobiol.* 2021;293:103724.
- 462 36. Teopompi E, Tzani P, Aiello M, Ramponi S, Visca D, Gioia MR, Marangio E, Serra W, Chetta
463 A. Ventilatory response to carbon dioxide output in subjects with congestive heart failure and in
464 patients with COPD with comparable exercise capacity. *Respir Care.* 2014;59:1034-1041.
- 465 37. Kominami K, Noda K, Minagawa N, Yonezawa K, Akino M. The concept of detection of
466 dynamic lung hyperinflation using cardiopulmonary exercise testing. *Medicine (Baltimore).*
467 2023;102:e33356.
- 468 38. Yoshiya I, Nakajima T, Nagai I, Jitsukawa S. A bidirectional respiratory flowmeter using the
469 hot-wire principle. *J Appl Physiol.* 1975;38:360-365.
- 470 39. Wasserman K, Hansen JE, Sue DY, Stringer WW, Sietsema KE, Sun X-G. Principles of
471 Exercise Testing and Interpretation: Including Pathophysiology and Clinical Application. 5th ed.
472 Philadelphia: Lippincott Williams & Wilkins; 2012.
- 473 40. Santoro C, Sorrentino R, Esposito R, Lembo M, Capone V, Rozza F, Romano M, Trimarco B,
474 Galderisi M. Cardiopulmonary exercise testing and echocardiographic exam: an useful
475 interaction. *Cardiovasc Ultrasound.* 2019;17:29.
- 476 41. Neder JA, Arbex FF, Alencar MC, O'Donnell CD, Cory J, Webb KA, O'Donnell DE. Exercise
477 ventilatory inefficiency in mild to end-stage COPD. *Eur Respir J.* 2015;45:377-387.

42. Gargiulo P, Apostolo A, Perrone-Filardi P, Sciomer S, Palange P, Agostoni P. A non invasive estimate of dead space ventilation from exercise measurements. *PLoS One*. 2014;9:e87395.
43. Murata M, Kobayashi Y, Adachi H. Examination of the Relationship and Dissociation Between Minimum Minute Ventilation/Carbon Dioxide Production and Minute Ventilation vs. Carbon Dioxide Production Slope. *Circ J*. 2021;86:79-86.
44. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I; NIHR RESPIRE Global Respiratory Health Unit. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. *Lancet Respir Med*. 2022;10:447-458.
45. Decramer M, Janssens W, Miravittles M. Chronic obstructive pulmonary disease. *Lancet*. 2012;379:1341-1351.
46. Frazão M, Silva PE, Frazão W, da Silva VZM, Correia MAV Jr, Neto MG. Dynamic Hyperinflation Impairs Cardiac Performance During Exercise in COPD. *J Cardiopulm Rehabil Prev*. 2019;39:187-192.
47. Cavaillès A, Brinchault-Rabin G, Dixmier A, Goupil F, Gut-Gobert C, Marchand-Adam S, Meurice JC, Morel H, Person-Tacnet C, Leroyer C, Diot P. Comorbidities of COPD. *Eur Respir Rev*. 2013;22:454-475.
48. Ritchie AI, Wedzicha JA. Definition, Causes, Pathogenesis, and Consequences of Chronic

496 Obstructive Pulmonary Disease Exacerbations. *Clin Chest Med.* 2020;41:421-438.

497

498

499 **Table 1. Data of participants' clinical characteristics**

		Total n=534		Convex n=129		Non-convex n=405		P value
		Mean±S.D	95% CI	Mean±S.D	95% CI	Mean±S.D	95% CI	
Sex	M:F	369:165		104:25		265:140		0.002
Age	[years]	67.0±12.9	[65.9-68.1]	68.2±11.7	[66.2-70.3]	66.6±13.3	[65.3-67.9]	0.215
Height	[cm]	161.9±9.2	[161.2-162.7]	163.1±9.0	[161.6-164.7]	161.5±9.2	[160.7-162.4]	0.087
Body weight [kg]		62.5±14.6	[61.3-63.7]	64.6±15.3	[62-67.2]	61.8±14.3	[60.4-63.2]	0.059
BMI		23.7±4.4	[23.3-24.1]	24.2±4.6	[23.4-24.9]	23.5±4.3	[23.1-24.0]	0.169
Ischemic								
heart disease		165 (30.9)		42 (32.6)		123 (30.4)		0.662
Valve								
disease		56 (10.5)		10 (7.8)		46 (11.4)		0.322
Chronic								
heart failure		154 (28.8)		43 (33.3)		111 (27.4)		0.267

Atrial								
fibrillation	32 (6.0)		10 (7.8)		22 (5.4)			0.393
Othres	52 (9.7)		14 (10.9)		38 (9.4)			0.612
Normal								
participants	97 (18.2)		20 (15.5)		77 (19.0)			0.432
LVEF	[%]	55.8±14.4	[54.6-57.0]	55.8±13.5	[53.4-58.2]	55.8±14.7	[54.3-57.2]	0.927
BNP	[pg/dL]	150.4±247.6	[126.8-174.0]	136.1±162.4	[104.9-167.3]	154.2±267.9	[125.1-183.2]	0.550
Smoking								
history	339 (63.5)		85 (65.9)		254 (62.7)			0.531
GOLD								
classification	[0:I:II:III:IV]	397:86:39:9:3		79:24:15:8:3		318:62:24:1:0		<0.001

500 Data are presented as mean ± S.D. and 95% CI. The convex group had more males and significantly

501 more severe cases according to the GOLD classification. No significant differences in other clinical

502 characteristics were observed between the two groups.

503 CI: confidence interval, BMI: body mass index, LVEF, Left ventricular ejection fraction, BNP: brain

504 natriuretic peptide, GOLD: Global Initiative for Chronic Obstructive Lung Disease

505

506

507 **Table 2 Cardiopulmonary exercise testing indices**

	Total n=534		Convex n=129		Non-convex n=405		p value	
	Mean±S.D	95% CI	Mean±S.D	95% CI	Mean±S.D	95% CI		
RPE – leg	17.2±2.3	[17.0-17.4]	16.7±2.4	[16.3-17.1]	17.3±2.3	[17.1-17.5]	0.011	
RPE - chest	15.9±2.6	[15.7-16.1]	16.0±2.5	[15.5-16.4]	15.9±2.7	[15.6-16.2]	0.755	
Peak VO ₂	[ml/min]	1057±536	[1011-1102]	1122±764	[990-1254]	1036±439	[993-1079]	0.112
Peak HR	[bpm]	125.1±25.5	[123.0-127.3]	125.9±23.7	[121.8-130.0]	124.9±26.1	[122.3-127.4]	0.698
Peak RER		1.15±0.1	[1.14-1.16]	1.13±0.09	[1.11-1.14]	1.16±0.1	[1.15-1.17]	0.001
ΔVO ₂ /ΔWR		8.8±1.9	[8.6-9.0]	8.7±1.9	[8.4-9.0]	8.8±1.9	[8.6-9.0]	0.540
VE/VCO ₂ slope		35.5±9.5	[34.7-36.3]	35.1±8.8	[33.6-36.7]	35.2±7.5	[34.5-36.0]	0.923
Y-intercept		4.3±3.3	[4.0-4.6]	4.6±3.0	[4.1-5.1]	4.4±2.9	[4.1-4.6]	0.423
minimum VE/VCO ₂		38.6±9.1	[36.5-40.6]	42.0±10.6	[37.4-46.7]	37.5±8.3	[35.3-39.7]	0.056

rest RR	17.0±4.4	[16.6-17.4]	17.6±3.5	[17-18.2]	16.8±4.6	[16.3-17.2]	0.070
peak RR	34.5±8.7	[33.8-35.3]	33.3±7.4	[32.1-34.6]	34.9±9.1	[34.0-35.8]	0.074
rest VD/VT	0.42±0.06	[0.41-0.42]	0.43±0.06	[0.42-0.44]	0.41±0.06	[0.41-0.42]	0.061
peak VD/VT	0.34±0.05	[0.34-0.35]	0.34±0.05	[0.33-0.35]	0.34±0.05	[0.34-0.35]	0.793
rest VO ₂ /HR	2.9±0.8	[2.9-3.0]	3.0±0.7	[2.9-3.1]	2.9±0.8	[2.8-3.0]	0.391
Peak VO ₂ /HR	8.1±2.8	[7.8-8.3]	8.3±2.7	[7.8-8.8]	8.0±2.8	[7.7-8.3]	0.348

508 Data are presented as mean ± S.D. and 95% CI. The rating of perceived exertion at the end of the

509 exercise test showed no difference in shortness of breath between the two groups. In contrast, lower

510 extremity fatigue was significantly lower in the convex group. Regarding the cardiopulmonary

511 exercise test indices, there were almost no differences between the two groups; however, the

512 minimum VE/VCO₂ ratio tended to be higher in the convex group.

513 CI, confidence interval; RPE, rate of perceived exertion; VO₂, oxygen uptake; VCO₂, carbon

514 dioxide; HR, heart rate; RER, respiratory exchange ratio; WR, work rate; RR, respiratory rate;

515 VD/VT, deadspace gas volume to tidal volume ratio.

516

517

518 **Table 3 Spirometry testing indices**

		Total n=534		Convex n=129		Non-convex n=405		p value
		Mean±S.D	95% CI	Mean±S.D	95% CI	Mean±S.D	95% CI	
VC	[L]	3.12±0.84	[3.05-3.19]	3.18±0.81	[3.04-3.32]	3.10±0.86	[3.01-3.18]	0.363
%VC	[%]	103.2±18.7	[101.6-104.8]	104.6±18.6	[101.3-107.8]	105.6±18.7	[103.8-107.4]	0.573
TV	[L]	0.91±0.37	[0.87-0.94]	0.94±0.45	[0.86-1.02]	0.90±0.34	[0.86-0.93]	0.246
ERV	[L]	0.96±0.48	[0.92-1.00]	0.95±0.44	[0.88-1.03]	0.96±0.49	[0.91-1.01]	0.872
%ERV	[%]	76.5±34.0	[73.6-79.3]	72.6±31.3	[67.2-78.0]	77.7±34.8	[74.3-81.1]	0.142
IRV	[L]	1.25±0.58	[1.20-1.30]	1.28±0.54	[1.19-1.37]	1.24±0.59	[1.18-1.30]	0.511
IC	[L]	2.16±0.64	[2.10-2.21]	2.22±0.63	[2.11-2.33]	2.14±0.64	[2.07-2.20]	0.207
FVC	[L]	3.06±0.85	[2.98-3.13]	3.11±0.83	[2.97-3.25]	3.04±0.85	[2.95-3.12]	0.395
%FVC	[%]	92.4±16.6	[91.0-93.8]	91.4±17.3	[88.5-94.4]	92.7±16.3	[91.1-94.3]	0.451
FEV1.0	[L]	2.26±0.72	[2.20-2.32]	2.17±0.74	[2.05-2.30]	2.28±0.71	[2.21-2.35]	0.130
%FEV1.0	[%]	101.5±23.4	[99.5-103.4]	96.2±28.0	[91.4-101.0]	103.1±21.5	[101.0-105.2]	0.003

FEV1.0%	[%]	73.7±10.4	[72.8-74.6]	69.4±13.1	[67.1-71.6]	75.0±9.0	[74.2-75.9]	0.000
MMF	[L/s]	2.02±1.06	[1.78-2.27]	1.64±0.83	[1.26-2.03]	2.10±1.06	[1.82-2.38]	0.100
%MMF	[%]	68.7±28.5	[62.2-75.2]	58.3±28.1	[45.3-71.3]	70.3±25.1	[63.7-77.0]	0.091
PEF	[L/s]	6.33±2.34	[5.80-6.86]	5.54±2.15	[4.60-6.48]	6.61±2.36	[5.99-7.24]	0.079
%PEF	[%]	83.6±23.1	[78.4-88.8]	72.8±24.8	[61.9-83.7]	87.5±21.4	[81.9-93.2]	0.014
MVV	[L/min]	68.6±25.7	[66.1-71.0]	74.8±30.3	[69-80.6]	81.0±28.3	[77.9-84.0]	0.058
%MVV	[%]	84.7±24.7	[82.4-87.0]	92.2±31.2	[86.2-98.2]	103.2±27.1	[100.3-106.1]	0.001

519 Data are presented as mean ± S.D. and 95% CI. The measured values of forced expiratory volume in
520 1 s as a percentage of forced vital capacity (FEV1.0%), predicted values of forced expiratory volume
521 in 1 s (%FEV1.0), peak expiratory flow (%PEF), and maximal ventilatory volume (%MVV) were
522 significantly lower in the convex group.

523 CI, confidence interval; VC, vital capacity; VT, tidal volume; ERV, expiratory reserve volume; IRV,
524 inspiratory reserve volume; IC, inspiratory capacity; FVC, forced vital capacity; FEV, forced
525 expiratory volume; FEV1.0, forced expiratory volume in 1 s; FEV1.0%, forced expiratory volume in
526 1 s as a percentage of forced vital capacity; MMF, maximal mid-expiratory flow; PEF, peak
527 expiratory flow; MVV, maximal ventilatory volume.

528

529

530 **Figure legend**

531

532 Figure 1 Correlation between respiratory function and CPET indices

533 The upper two panels show the relationship between FEV1.0% and the Y-intercept of VE/VCO₂ in

534 the convex group (A-1) and the non-convex group (A-2). The lower two panels show the

535 relationship between FEV1.0% and the difference between the minimum VE/VCO₂ and VE/VCO₂

536 slopes in the convex group (B-1) and non-convex groups (B-2).

537

